Daewoong Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 01:23 am EST
Share
Daewoong Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 461,517.52 million compared to KRW 432,805.98 million a year ago. Net income was KRW 39,307.31 million compared to KRW 38,905.58 million a year ago. Basic earnings per share from continuing operations was KRW 940 compared to KRW 936 a year ago. Basic earnings per share was KRW 940 compared to KRW 936 a year ago.
For the nine months, sales was KRW 12,426.73 million compared to KRW 10,266.48 million a year ago. Net income was KRW 114,861.22 million compared to KRW 94,378.29 million a year ago. Basic earnings per share from continuing operations was KRW 2,757 compared to KRW 2,270 a year ago. Basic earnings per share was KRW 2,757 compared to KRW 2,270 a year ago.
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
DAEWOONG CO., LTD. 
